State of New Jersey Common Pension Fund D Purchases Shares of 113,683 TG Therapeutics, Inc. (NASDAQ:TGTX)

State of New Jersey Common Pension Fund D acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, according to its most recent filing with the SEC. The firm acquired 113,683 shares of the biopharmaceutical company’s stock, valued at approximately $2,022,000. State of New Jersey Common Pension Fund D owned about 0.07% of TG Therapeutics as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in TG Therapeutics during the 2nd quarter valued at $124,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics during the second quarter valued at about $35,000. Strategic Financial Concepts LLC bought a new position in TG Therapeutics in the second quarter worth about $530,000. Los Angeles Capital Management LLC lifted its holdings in TG Therapeutics by 20.4% in the second quarter. Los Angeles Capital Management LLC now owns 92,277 shares of the biopharmaceutical company’s stock worth $1,642,000 after buying an additional 15,661 shares during the period. Finally, Arizona State Retirement System boosted its position in TG Therapeutics by 3.9% during the 2nd quarter. Arizona State Retirement System now owns 41,069 shares of the biopharmaceutical company’s stock valued at $731,000 after acquiring an additional 1,539 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group raised their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Trading Down 2.5 %

NASDAQ TGTX opened at $24.65 on Friday. The stock’s fifty day moving average price is $22.01 and its 200-day moving average price is $18.30. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The stock has a market cap of $3.81 billion, a P/E ratio of 107.17 and a beta of 2.21. TG Therapeutics, Inc. has a 12 month low of $6.46 and a 12 month high of $26.41.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. During the same period last year, the business earned ($0.34) EPS. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.